Compare Gold Fields Limited (GFI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Merck & Co., Inc. — how do they compare? Gold Fields Limited trades at $36.84 (market cap $31.87B), while Merck & Co., Inc. trades at $146.49 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 11× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Merck & Co., Inc. for 98 Days on average.
| GFI | MRK | |
|---|---|---|
Market Cap | $31.87B | $351.28B |
Volume | 4,169,651 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $156.43 |
52-Week Low | $31.25 | $82.49 |
Typical Hold Time | 49 Days | 98 Days |
Enterprise Value | $32.47B | $398.04B |
Dividend Yield | 6% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.70, up 4.71% over 24 hours, but technical indicators signal a bearish trend with price near support at $35. The company reported strong 2025 results with revenue of $8.75 billion and net income of $3.57 billion, yielding high profitability margins. However, recent earnings misses and a rejected $27 billion takeover bid for Northern Star have introduced volatility. Analyst consensus remains positive with a $52.75 price target, but the stock faces headwinds from acquisition-related uncertainty and mixed technical signals.
GFI presents a compelling value case with low P/E of 7.3 and robust cash flow growth, but investors must weigh execution risks from its aggressive M&A strategy and recent earnings inconsistencies against its strong fundamentals and shareholder returns. The stock's near-term direction hinges on merger outcomes and gold price stability.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
